Facebook
Instagram
Linkedin
Pinterest
Twitter
Youtube
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Tag: European Medicines Agency (EMA)
ARS Responds to FDA’s Request for Additional Study Before Approving neffy...
Dave Bloom
-
2023/09/20
FDA Issues Complete Response Letter for neffy® New Drug Application with Request for Additional Study.
Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase...
Dave Bloom
-
2021/12/22
The patch therapy remains in regulatory limbo.
FDA Wants More Viaskin Peanut Data Resulting in Further Approval Delays
Dave Bloom
-
2021/10/27
Delays mount pushing trials of modified patch.
Emergency Epinephrine Nasal Spray Takes Final Step Toward Approval in EU
Dave Bloom
-
2020/11/30
A needle-free option for administration of epinephrine is on the horizon.
Viaskin Peanut “Patch” Therapy Takes Next Step Toward Approval… in Europe
Dave Bloom
-
2020/11/03
The Marketing Authorization Application for Viaskin™ Peanut was validated by the European Medicines Agency.
Results of Aimmune’s Pivotal Phase 3 European Trial of PALFORZIA® Published...
News Wire ~ 3rd Party Press Release
-
2020/07/21
Peanut-allergic patients treated with Palforzia showed desensitization to peanut protein with a predictable safety profile at nine months